Long-term follow-up (up to 11 years) of an Italian pediatric MS cohort treated with Natalizumab: a multicenter, observational study
- 4 July 2022
- journal article
- research article
- Published by Springer Nature in Neurological Sciences
- Vol. 43 (11) , 6415-6423
Abstract
Background Natalizumab (NAT) has a strong impact on disease activity of aggressive pediatric multiple sclerosis (MS), with no difference in safety profile compared to adult MS. However, available data are limited by short follow-up. Our aim was to report long-term follow-up data (up to 11 years) of a large Italian pediatric MS cohort treated with NAT. Materials and methods We retrospectively collected data of pediatric MS patients treated with NAT included in a previous study and prospectively followed in Italian MS centers. We compared disease activity pre, during, and post-NAT and we performed survival analyses of time to evidence of disease activity (EDA) during NAT, time to reach EDA post-NAT, and time to NAT discontinuation. Results Ninety-two patients were included from 19 MS centers in Italy. At NAT initiation, cohort’s characteristics were as follows: 55 females; 14.7 ± 2.4 (mean ± SD) years of age; 34 naïve to disease modifying therapies; 1-year pre-NAT annualized relapse rate (ARR): 2.2 ± 1.2; EDSS (median [IQR]): 2.5 [2.0–3.0]; gadolinium-enhancing lesions: 2 [1–5]; 41 JCV positives. During NAT treatment (61.9 ± 35.2 mean infusions), ARR lowered to 0.08 ± 0.23 (p < 0.001), EDSS score to 1.5 [1.0–2.5] at last infusion (p < 0.001), and 51% patients had EDA (21% after 6 months of rebaseline). No serious adverse events were reported. Forty-nine patients discontinued NAT, mainly due to PML concern; the majority (29/49) had disease reactivation in the subsequent 12 months, of which three with a clinical rebound. Conclusion NAT treatment maintains its high efficacy for a long time in pediatric MS patients, with no new safety issues.Keywords
This publication has 25 references indexed in Scilit:
- Clinical Characteristics of Pediatric-Onset and Adult-Onset Multiple Sclerosis in Hispanic AmericansJournal of Child Neurology, 2016
- Natalizumab in the pediatric MS population: results of the Italian registryBMC Neurology, 2015
- Cognitive and patient-reported outcomes in adults with pediatric-onset multiple sclerosisMultiple Sclerosis Journal, 2015
- Elevated relapse rates in pediatric compared to adult MS persist for at least 6 yearsMultiple Sclerosis and Related Disorders, 2014
- Predicting autoimmunity after alemtuzumab treatment of multiple sclerosisJournal of Neurology, Neurosurgery & Psychiatry, 2013
- Natalizumab Therapy for Highly Active Pediatric Multiple SclerosisJAMA Neurology, 2013
- Natalizumab use in pediatric patients with relapsing-remitting multiple sclerosisEuropean Journal of Paediatric Neurology, 2013
- Long-term outcome of paediatric-onset multiple sclerosis: a population-based studyJournal of Neurology, Neurosurgery & Psychiatry, 2012
- Increased Relapse Rate in Pediatric-Onset Compared With Adult-Onset Multiple SclerosisArchives of Neurology, 2009
- Natural History of Multiple Sclerosis with Childhood OnsetNew England Journal of Medicine, 2007